Impact of first-line sildenafil monotreatment for pulmonary arterial hypertension.
Yanagisawa R, Kataoka M, Taguchi H et al.
In this study, the authors evaluated the efficacy of sildenafil as a first-line monotherapy for pulmonary hypertension (PH). Sildenafil is a phosphodiesterase-5 inhibitor that is given orally for the treatment of PH. It has relatively few side-effects, is well-tolerated, and is safe for patients with moderate renal or hepatic dysfunction.